share_log

Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target

Moomoo 24/7 ·  Apr 22 13:29

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and maintains $45 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment